| |
| Device | FoundationOne CDx (F1CDx) |
| Generic Name | Next generation sequencing oncology panel, somatic or germline variant detection system |
| Applicant | Foundation Medicine, Inc. 400 Summer St. Boston, MA 02210 |
| PMA Number | P170019 |
| Supplement Number | S050 |
| Date Received | 11/03/2023 |
| Decision Date | 12/01/2023 |
| Product Code |
PQP |
| Advisory Committee |
Pathology |
| Supplement Type | Normal 180 Day Track No User Fee |
| Supplement Reason | Postapproval Study Protocol |
| Expedited Review Granted? | No |
| Combination Product | No |
| Predetermined Change Control Plan Authorized | No |
Approval Order Statement Approval of the clinical protocol entitled FoundationOne®CDx Clinical Validation Protocol RET Fusions Clinical Efficacy Post-Approval Study for Selpercatinib |